Lidocaine Hydrochloride Jelly, USP,2%

/Lidocaine Hydrochloride Jelly, USP,2%
Lidocaine Hydrochloride Jelly, USP,2%2018-09-06T09:12:40+00:00

Prescription Drug Name:

Lidocaine Hydrochloride Jelly, USP,2%

ID:

76b5a233-4450-4827-964d-b5c30174e003

Code:

34391-3

DESCRIPTION


id: a81d5c14-e961-462c-aa0e-3a1e0f46e6fa
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3

Lidocaine HCl 2% Jelly is a sterile, aqueous product that contains a local anesthetic agent and is administered topically. (See INDICATIONS for specific uses.) Lidocaine HCl 2% Jelly contains lidocaine HCl which is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, monohydrochloride and has the following structural formula: Its molecular formula is C14H22N2O • HCl and its molecular weight is 270.80. Lidocaine HCl 2% Jelly also contains hypromellose, and the resulting mixture maximizes contact with mucosa and provides lubrication for instrumentation. The unused portion should be discarded after initial use. Composition of Lidocaine HCl 2% Jelly 30 mL and 5 mL tubes: Each mL contains 20 mg of lidocaine HCl. The formulation also contains methylparaben, propylparaben, hypromellose, and sodium hydroxide and/or hydrochloric acid to adjust pH between 6.0 to 7.0.

INDICATIONS AND USAGE


id: 19d393d8-61a6-43a3-8832-e5bcd5ced8a0
displayName: INDICATIONS & USAGE SECTION
FDA Article Code: 34067-9

Lidocaine HCl 2% Jelly is indicated for prevention and control of pain in procedures involving the male and female urethra, for topical treatment of painful urethritis, and as an anesthetic lubricant for endotracheal intubation (oral and nasal).

CONTRAINDICATIONS


id: 8309d8a5-df67-4ae5-8868-eda91fa9d5fb
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3

Lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of Lidocaine HCl 2% Jelly.

WARNINGS


id: 7f837112-e110-4139-842d-c32e3c7a3669
displayName: WARNINGS SECTION
FDA Article Code: 34071-1

EXCESSIVE DOSAGE, OR SHORT INTERVALS BETWEEN DOSES, CAN RESULT IN HIGH PLASMA LEVELS AND SERIOUS ADVERSE EFFECTS. PATIENTS SHOULD BE INSTRUCTED TO STRICTLY ADHERE TO THE RECOMMENDED DOSAGE AND ADMINISTRATION GUIDELINES AS SET FORTH IN THIS PACKAGE INSERT. THE MANAGEMENT OF SERIOUS ADVERSE REACTIONS MAY REQUIRE THE USE OF RESUSCITATIVE EQUIPMENT, OXYGEN AND OTHER RESUSCITATIVE DRUGS. Lidocaine HCl 2% Jelly should be used in extreme caution in the presence of sepsis or severely traumatized mucosa in the area of application since under such conditions there is the potential for rapid systemic absorption. When used for endotracheal tube lubrication care should be taken to avoid introducing the product into the lumen of the tube. Do not use the jelly to lubricate the endotracheal stylettes. If allowed into the inner lumen, the jelly may dry on the inner surface leaving a residue which tends to clump with flexion, narrowing the lumen. There have been rare reports in which this residue has caused the lumen to occlude. (See also ADVERSE REACTIONS and DOSAGE AND ADMINISTRATION.)

ADVERSE REACTIONS


id: e5e9ec08-ad60-4de4-87af-ee44f1d47ac2
displayName: ADVERSE REACTIONS SECTION
FDA Article Code: 34084-4

Adverse experiences following the administration of lidocaine are similar in nature to those observed in other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage or rapid absorption, or may result from a hypersensitivity, idiosyncrasy, or diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported: There have been rare reports of endotracheal tube occlusion associated with the presence of dried jelly residue in the inner lumen of the tube. (See also WARNINGS and DOSAGE AND ADMINISTRATION.)

OVERDOSAGE


id: 837122ce-58ff-4d33-a8c6-a257d257bf1b
displayName: OVERDOSAGE SECTION
FDA Article Code: 34088-5

Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics. (See ADVERSE REACTIONS, WARNINGS, and PRECAUTIONS.)

DOSAGE AND ADMINISTRATION


id: a08a8154-5dc6-4325-a77e-5a13b7301ea7
displayName: DOSAGE & ADMINISTRATION SECTION
FDA Article Code: 34068-7

When Lidocaine HCl 2% Jelly is used concomitantly with other products containing lidocaine, the total dose contributed by all formulations must be kept in mind. The dosage varies and depends upon the area to be anesthetized, vascularity of the tissues, individual tolerance, and the technique of anesthesia. The lowest dosage needed to provide effective anesthesia should be administered. Dosages should be reduced for children and for elderly and debilitated patients. Although the incidence of adverse effects with Lidocaine HCl 2% Jelly is quite low, caution should be exercised, particularly when employing large amounts, since the incidence of adverse effects is directly proportional to the total dose of local anesthetic agent administered.

MAXIMUM DOSAGE


id: 13b4e4b4-fb33-4c56-befb-3e7d9e90c79d
displayName: SPL UNCLASSIFIED SECTION
FDA Article Code: 42229-5

No more than 600 mg of lidocaine HCl should be given in any 12 hour period.

HOW SUPPLIED


id: 189232ab-796d-43c0-821a-aa5ca03d6bdf
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5

Product: 50090-0555 NDC: 50090-0555-0 30 mL in a TUBE, WITH APPLICATOR

Lidocaine Hydrochloride


id: 525a18a0-587c-4986-8143-5dc08b4b280b
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4